Abstract:e14244 Background: Preclinical and clinical studies have shown that prior receipt of radiotherapy enhances antitumor immune responses, a phenomenon we call the “radio-memory effect.” However, all of the evidence regarding this effect to date comes from work with anti-PD-1 or anti-PD-L1 inhibitors. Here we explore whether this effect also occurs with other forms of immune therapy, specifically interleukin-2 (IL-2). If so, whether this triple combination therapy could produce synergetic anti-tumor effect. Methods: 1. Clinical work: we retrospectively assessed outcomes in patients with malignant peritoneal effusion (MPE) who had previously received radiotherapy for colon or rectum cancer within 18 months before the intrapleural infusion of IL-2 or cisplatin. All patients received intrapleural infusion of IL-2 or cisplatin, and most had had several cycles of standard chemotherapy for colon or rectum cancer. 2. Translational work: MC38 cell line (5×106) was subcutaneously inoculated into the right lower extremity of C57/BL mice to construct a primary tumor model. Six days later, MC38 cell line (1×106) was subcutaneously inoculated into the left lower limb to construct a second tumor model. The main research is as follows: To explore the optimal radiation dose and fraction for radiotherapy; Whether the addition of IL-2 will further enhance the efficacy of radiotherapy combined with anti-PD-1; To explore the optimal combination model of radiation, anti-PD-1 and IL-2; Whether the addition of IL-2 will increase the abscopal effect produced by radiotherapy and anti-PD-1. Results: 1. We identified 3,747 patients with MPE (median age 66 years [range 24–81)) treated at one of several institutions from August 2009 through May 2016; 412 patients had been treated with IL-2 and 592 with cisplatin and had survived for at least 3 months afterward. 2. Hypofractionated radiotherapy (12Gy × 2) combined with IL-2 is better; IL-2 will enhance the efficacy of radiotherapy combined with anti-PD-1; IL-2 and anti-PD-1 followed by radiotherapy might maximize the anti-tumor effect; IL-2 might increase the abscopal effect produced by radiotherapy combined with anti-PD-1. Conclusions: We speculate that previous radiotherapy could enhance the efficacy of IL-2 and the anti-tumor effect produced by radiotherapy combined with anti-PD-1 could be enhanced by IL-2. The “radio-memory” effect could be beneficial in future studies.

Biological foundation and research progress on radiotherapy combined with immuno-therapy

Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade

Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy

Recent Research Progress of Abscopal Effect in Tumor Radiotherapy

Killing two birds with one stone: Abscopal Effect Mechanism and its application prospect in radiotherapy

The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances

Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors

Radiotherapy combined with immunotherapy: the dawn of cancer treatment

Research Advances in Radiotherapy Combined with Immunotherapy for Cancer

Immune mechanisms mediating abscopal effects in radioimmunotherapy

Research Progress and Clinical Significance of Abscopal Effect of Radiotherapy

Abscopal Effect of Stereotactic Radiotherapy Combined with Anti‐pd‐1/pd‐l1 Immunotherapy: Mechanisms, Clinical Efficacy, and Issues

[Abscopal effect: Myth or reality?]

Abscopal Effects of Local Radiotherapy Are Dependent on Tumor Immunogenicity

Radiotherapy combined with immunotherapy could improve the immune infiltration of melanoma in mice and enhance the abscopal effect

Pivotal roles of tumor‐draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy

Interleukin-2 Boosts Local and Abscopal Antitumor Effect of Radiotherapy Combined with Anti-Pd-1: A Translational Research from Clinical Radio-Memory Effect.

Effect of hypofractionated radiotherapy, PD-1 immunotherapy, and anti-angiogenic therapy on abscopal responses and the tumor microenvironment.

Nanotechnology-enhanced radiotherapy and the abscopal effect: Current status and challenges of nanomaterial-based radio-immunotherapy

Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer